Pfizer Oncology, San Diego, CA 92121, USA.
Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44106, USA.
Future Oncol. 2020 Jun;16(17):1199-1210. doi: 10.2217/fon-2020-0212. Epub 2020 May 4.
Immunomodulatory mechanisms contributing to angiogenic inhibition in renal tumors are not well characterized. We report associations between efficacy and tumor-associated immune cells and mRNA/miRNA expression in patients from AXIS. Immunohistochemistry (n = 52) and mRNA/miRNA expression analyses (n = 72) were performed on tumor samples. In axitinib-treated patients, higher and expression, respectively, was associated with longer progression-free survival (hazard ratio; 95% CI: 0.3; 0.1-0.8 and 0.4; 0.2-0.9) and showed interaction with treatment (p = 0.029 and p < 0.001); lower expression was associated with objective response (odds ratio: 0.1; 95% CI: 0.01-1.0) and longer overall survival (hazard ratio: 3.9; 95% CI: 1.4-10.3). , and expression levels may be prognostic/predictive of clinical benefit with axitinib. ClinicalTrials.gov NCT00678392.
在肾肿瘤中导致血管生成抑制的免疫调节机制尚未很好地确定。我们报告了 AXIS 患者中疗效与肿瘤相关免疫细胞和 mRNA/miRNA 表达之间的相关性。对肿瘤样本进行了免疫组织化学（n = 52）和 mRNA/miRNA 表达分析（n = 72）。在接受阿昔替尼治疗的患者中，分别较高的 和 表达与无进展生存期更长相关（风险比；95%置信区间：0.3；0.1-0.8 和 0.4；0.2-0.9），并与治疗存在交互作用（p = 0.029 和 p < 0.001）；较低的 表达与客观缓解相关（优势比：0.1；95%置信区间：0.01-1.0）和总生存期更长相关（风险比：3.9；95%置信区间：1.4-10.3）。 和 的表达水平可能是阿昔替尼临床获益的预后/预测指标。ClinicalTrials.gov NCT00678392。
Zotero 插件